- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
A New Decision Support Tool for Surgical Oncology Launched
A pathways company has followed up its medical and radiation oncology clinical decision tools with a new surgical oncology platform.
Clinical pathways are rapidly being adopted by providers and payers alike, to guide treatment decisions and also manage care costs. Via Oncology, a company that develops these clinical pathways using its in-house expertise of physicians, has announced the launch of a Surgical Oncology Pathways platform, which follows similar platforms for medical and radiation oncology.
In an associated press release the company said that the new platform is initially being rolled out at UPMC and Indiana University Health, for 6 diseases, incorporating key decision points for patient work-up and assessment along with surgical interventions and follow up surveillance plans.
According to Kathy Lokay, CEO and President of Via Oncology, “The Via Pathways program has been central to the quality of care in medical and radiation oncology and we are excited to expand it for use by surgical oncologists as well.”
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More
Higher UTI Risk After Spinal Fusion in Patients With Certain Comorbidities
March 5th 2025A study investigated the incidence of postoperative urinary tract infections (UTIs) in patients undergoing spinal fusion for deformities, finding that patients with more than 12 levels fused had the highest UTI rates.
Read More
